Zoledronic acid as compared with observation in Multiple Myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

Disclosures: This work was supported with an unrestricted grant from NOVARTIS FARMACEUTICA S.A., Barcelona, Spain. Part of the work was also done thanks to the grants PS09/01450 and PI12/02311 from the Spanish “Instituto de Salud Carlos III (ISCIII)”, the grant RD12/0036/0069 from “Red Temática de Investigación Cooperativa en Cáncer (RTICC), and grant GCB-120981SAN from the “Asociación Española Contra el Cáncer (AECC)” that financed some of the biological data of these patients.

Contributions: RG-S and JFSM were the initial designers of the study. MVM was involved in the initial launch of the study, provided strong documental and scientific support and helped in the statistical and clinical interpretation of the data. AO, MJM, JdlR, AR, MTH, LP, AIT, MJB, MG, PR, JB, EA, MG, EMO, and JMR, were clinicians responsible for the patients and those who took care of the protocol accomplishment, sampling and collection of clinical data. RG-S and MVM prepared the initial version of the paper. JFSM and RG-S were the main responsible of the global group. JFSM was the main representative of the GEM/PETHEMA group. RG-S, JFSM and MVM were the persons responsible of the final revision of the draft, as well as the persons who gave the final approval of the version to be published.